著者
Kei Sawada Shigehiro Karashima Mitsuhiro Kometani Rie Oka Yoshimichi Takeda Toshitaka Sawamura Aya Fujimoto Masashi Demura Ayako Wakayama Mikiya Usukura Kunimasa Yagi Yoshiyu Takeda Takashi Yoneda
出版者
The Japan Endocrine Society
雑誌
Endocrine Journal (ISSN:09188959)
巻号頁・発行日
pp.EJ17-0440, (Released:2018-02-20)
被引用文献数
28

Obstructive sleep apnea syndrome (OSAS) is often associated with metabolic disorders such as obesity and type 2 diabetes and may contribute to cardiovascular events. A novel class of antidiabetic drugs, the sodium glucose cotransporter 2 inhibitors (SGLT2i) reduce body weight (BW), although there is limited data on their impact on OSAS. We therefore evaluated the effect of SGLT2i on OSAS in patients with type 2 diabetes. The presented study was a retrospective design in 18 patients with type 2 diabetes with OSAS (4 males, age range 39–81 yr) administrated a SGLT2i. HbA1c, BW, body mass index (BMI), blood pressure (BP) and apnea hypopnea index (AHI) were evaluated before and after SGLT2i administration. The relationships between the reduction in AHI and the other variables were examined using Pearson correlation analysis. We have got result that SGLT2i reduced AHI from 31.9 ± 18.0 to 18.8 ± 11.5 events per hr (p = 0.003). HbA1c, BW and BMI decreased significantly, whereas BP did not. The Pearson correlation analysis showed a significant relationship between the reduction in AHI and pre-administration of AHI. In conclusion, SGLT2i reduced not only HbA1c, BW and BMI but also AHI significantly and therefore has potential as an effective treatment of OSAS.

言及状況

外部データベース (DOI)

Twitter (25 users, 25 posts, 40 favorites)

SGLT2阻害薬はHbA1c,体重,BMIのみならず無呼吸低呼吸指数を有意に減少させ,睡眠時無呼吸症候群に対する潜在的治療効果を有する可能性がある.2型糖尿病に睡眠時無呼吸症候群を合併した18例後ろ向き研究.(Endocr J 2018, PMID:29459554) https://t.co/7ENC7mYJmB

収集済み URL リスト